Civil Rights
Movements, leaders, victories and the continuing fight for equality.
Explore the people, places, events, achievements, struggles and stories that shaped our journey.
Movements, leaders, victories and the continuing fight for equality.
Innovation, patents, science, technology and world-changing contributions.
Pioneers, champions, Negro Leagues, records, activism and excellence.
Meet the people whose lives, choices and achievements shaped the journey.
Black towns, communities, institutions and places where history happened.
Moments that changed communities, movements, institutions and the nation.
Mansa Musa was the ruler of the Mali Empire in West Africa. Details recorded here should be sourced; unknown information is left blank.
MORE →Reflects the personal views, recollections, and perspective of the author, Mike Davis.
This is a personal recollection on the Move fire on May 13, 1985
A reuptake modulator, or transporter modulator, is a type of drug which modulates the reuptake of one or more neurotransmitters via their respective neurotransmitter transporters.[1] Examples of reuptake modulators include reuptake inhibitors (transporter blockers)[2] and reuptake enhancers.[3]
Source: Wikipedia. Article content is retrieved live through the MediaWiki API.
A reuptake modulator, or transporter modulator, is a type of drug which modulates the reuptake of one or more neurotransmitters via their respective neurotransmitter transporters. Examples of reuptake modulators include reuptake inhibitors (transporter blockers) and reuptake enhancers.
MTHPI, also known as 3-(1-methyl-1,2,3,6-tetrahydropyrid-4-yl)indole (3-MTPI), is a serotonin receptor modulator of the tetrahydropyridinylindole group related to the psychedelic drug dimethyltryptamine (DMT). Though it is not technically a tryptamine itself, MTHPI can be regarded as a constrained analogue of DMT. The drug shows affinity for the serotonin 5-HT1, 5-HT1A, and 5-HT2A receptors (Ki = 217 nM, 144 nM, and 71 nM, respectively). Its affinity for the serotonin 5-HT2A receptor was 8-fold higher than that of DMT. Besides serotonin receptors, MTHPI also shows affinity for the serotonin transporter (SERT) (IC50Tooltip half-maximal inhibitory concentration = 690 nM). The chemical synthesis of MTHPI has been described. Derivatives of MTHPI such as 5-MeO-MTHPI, 2-Me-MTHPI, and 5-MeO-2-Me-MTHPI have also been described. 5-MeO-MTHPI showed 11-fold lower affinity for the serotonin 5-HT2A receptor and 6-fold higher affinity for the serotonin 5-HT1A receptor compared to MTHPI. Conversely, the 2-methylated analogues showed markedly reduced affinities for the assessed serotonin receptors. Various other derivatives of MTHPI, acting as monoamine transporter modulators, have been described as well. MTHPI was first described in the scientific literature by Ethan Will Taylor and colleagues by 1987.
TACT411 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. The exact chemical structure of TACT411 does not yet appear to have been disclosed, but it may be a substituted benzofuran derivative.
1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator of the indolizinylethylamine family. It is an analogue of BK-NM-AMT (β-keto-N-methyl-α-methyltryptamine) in which the indole ring has been replaced with an indolizine ring. 1Z2MAP1O has been found to be a serotonin and dopamine releasing agent as well as a weak serotonin 5-HT1B receptor agonist and serotonin 5-HT2B receptor antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47 screened targets. The drug's EC50Tooltip half-maximal effective concentration values for induction of monoamine release were 109 nM for serotonin and 227 nM for dopamine in Chinese hamster ovary (CHO) cells expressing the human monoamine transporters (MATs). The dopamine/serotonin ratio was 0.48. Its EC50 at the serotonin 5-HT1B receptor was 1,130 nM, whereas its IC50Tooltip half-maximal inhibitory concentration values were 2,140 nM at the serotonin 5-HT2B receptor, 2,410 nM at the dopamine transporter (DAT), and 5,690 nM at the norepinephrine transporter (NET). 1Z2MAP1O's inhibition of the serotonin transporter (SERT) was not reported. 1Z2MAP1O was patented by Matthew Baggott of Tactogen in 2023.
Before the 1921 destruction of Tulsa’s Greenwood District, Black residents had created a remarkable center of business and community life. The district included stores, professional offices, entertainment venues and homes owned by Black citizens. Understanding Greenwood means learning what was built—not only what was burned.
MORE →The Greenwood District.